Tecemotide

Drug Profile

Tecemotide

Alternative Names: BLP25 liposomal vaccine; EMD-531444; Emepepimut-S; L-BLP25; LP-BLP-25; ONO-7165; Stimuvax

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Biomira
  • Developer EMD Serono; Merck KGaA; Merck Serono Co Ltd; National Cancer Institute (USA); Oncothyreon; Ono Pharmaceutical
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants; Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Rectal cancer

Most Recent Events

  • 01 Oct 2016 EMD Serono and the National Cancer Institute completes a phase II trial for Prostate cancer (First-line therapy, Newly diagnosed, Combination therapy) in USA (NCT01496131)
  • 15 Mar 2016 Biomarkers information updated
  • 31 Oct 2015 Discontinued - Phase-II for Prostate cancer (First-line therapy) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top